The study validated two key PPARγ target genes, PRKCZ and PGK1, which were repressed upon PPARγ activation by its natural ligand, 15d-PGJ2, in three prostate cancer cell lines. The gene discussed is PRKCZ; the disease is prostate carcinoma.